Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalia Zisman

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Chemotherapy Research and Practice|February 8, 2012
Optimizing Liposomal Cisplatin Efficacy through Membrane Composition ManipulationsNatalia Zisman, Nancy Dos Santos, Sharon Johnstone, et al.
Leukemia Research|August 5, 2008
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacyPaul Tardi, Sharon Johnstone, Natashia Harasym, et al.
Molecular Cancer Therapeutics|August 13, 2009
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivoPaul G Tardi, Nancy Dos Santos, Troy O Harasym, et al.
Journal of Cancer|September 27, 2013
The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma modelElizabeth Donohue, Anitha Thomas, Norbert Maurer, et al.
Bioorganic & Medicinal Chemistry Letters|May 19, 2015
Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assaySteve Arns, Jason Tan, Sharon Sun, et al.
Bioorganic & Medicinal Chemistry Letters|July 7, 2016
Corrigendum to "Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay" [Bioorg. Med. Chem. Lett. 25 (2015) 2505-2509]Steve Arns, Jason Tan, Sharon Sun, et al.
Pediatric Blood & Cancer|August 14, 2013
Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastomaMary Rose Pambid, Rachel Berns, Hans H Adomat, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Chemotherapy Research and Practice|February 8, 2012
Optimizing Liposomal Cisplatin Efficacy through Membrane Composition ManipulationsNatalia Zisman, Nancy Dos Santos, Sharon Johnstone, et al.
Leukemia Research|August 5, 2008
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacyPaul Tardi, Sharon Johnstone, Natashia Harasym, et al.
Molecular Cancer Therapeutics|August 13, 2009
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivoPaul G Tardi, Nancy Dos Santos, Troy O Harasym, et al.
Journal of Cancer|September 27, 2013
The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma modelElizabeth Donohue, Anitha Thomas, Norbert Maurer, et al.
Bioorganic & Medicinal Chemistry Letters|May 19, 2015
Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assaySteve Arns, Jason Tan, Sharon Sun, et al.
Bioorganic & Medicinal Chemistry Letters|July 7, 2016
Corrigendum to "Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay" [Bioorg. Med. Chem. Lett. 25 (2015) 2505-2509]Steve Arns, Jason Tan, Sharon Sun, et al.
Pediatric Blood & Cancer|August 14, 2013
Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastomaMary Rose Pambid, Rachel Berns, Hans H Adomat, et al.
Pageof 1